Somewhat Positive Press Coverage Extremely Likely to Affect Telesta Therapeutics (TSE:TST) Share Price

Headlines about Telesta Therapeutics (TSE:TST) have trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than 6,000 news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Telesta Therapeutics earned a media sentiment score of 1.25 on their scale. InfoTrie also assigned news headlines about the biotechnology company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.

Telesta Therapeutics has a 52-week low of C$0.69 and a 52-week high of C$0.14.

About Telesta Therapeutics

Telesta Therapeutics Inc is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer.

Recommended Story: What are the economic characteristics of a bear market?

Receive News & Ratings for Telesta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.